Cargando…
The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT)
Multiple System Atrophy—Parkinsonism Predominant (MSA-P) and Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) are the clinical manifestations of atypical parkinsonism. Currently, there are no efficient in vivo methods available relating to neuroimaging or biochemical analysis in the e...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871165/ https://www.ncbi.nlm.nih.gov/pubmed/35204476 http://dx.doi.org/10.3390/diagnostics12020385 |
_version_ | 1784656931636379648 |
---|---|
author | Alster, Piotr Nieciecki, Michał Migda, Bartosz Kutyłowski, Michał Madetko, Natalia Duszyńska-Wąs, Karolina Charzyńska, Ingeborga Koziorowski, Dariusz Królicki, Leszek Friedman, Andrzej |
author_facet | Alster, Piotr Nieciecki, Michał Migda, Bartosz Kutyłowski, Michał Madetko, Natalia Duszyńska-Wąs, Karolina Charzyńska, Ingeborga Koziorowski, Dariusz Królicki, Leszek Friedman, Andrzej |
author_sort | Alster, Piotr |
collection | PubMed |
description | Multiple System Atrophy—Parkinsonism Predominant (MSA-P) and Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) are the clinical manifestations of atypical parkinsonism. Currently, there are no efficient in vivo methods available relating to neuroimaging or biochemical analysis in the examination of these entities. Among the advanced methods available, using positron emission tomography is constrained by high cost and low accessibility. In this study the authors examined patients with two types of atypical parkinsonism—MSA-P and PSP-P, which are difficult to differentiate, especially in the early years of their development. The aim of this study was to assess whether the examination of patients in the period following the early years (3–6-year duration of symptoms) could be enhanced by perfusion single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI) or evaluation of cognitive abilities. Extended examination using MRI and perfusion SPECT showed that the evaluation of the mesencephalon/pons ratio, mesencephalic volume decrease, the Magnetic Resonance Parkinsonism Index (MRPI) and frontal perfusion should be considered more feasible than screening cognitive evaluation in MSA-P and PSP-P with a 3–6-year duration of symptoms. |
format | Online Article Text |
id | pubmed-8871165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88711652022-02-25 The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT) Alster, Piotr Nieciecki, Michał Migda, Bartosz Kutyłowski, Michał Madetko, Natalia Duszyńska-Wąs, Karolina Charzyńska, Ingeborga Koziorowski, Dariusz Królicki, Leszek Friedman, Andrzej Diagnostics (Basel) Article Multiple System Atrophy—Parkinsonism Predominant (MSA-P) and Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) are the clinical manifestations of atypical parkinsonism. Currently, there are no efficient in vivo methods available relating to neuroimaging or biochemical analysis in the examination of these entities. Among the advanced methods available, using positron emission tomography is constrained by high cost and low accessibility. In this study the authors examined patients with two types of atypical parkinsonism—MSA-P and PSP-P, which are difficult to differentiate, especially in the early years of their development. The aim of this study was to assess whether the examination of patients in the period following the early years (3–6-year duration of symptoms) could be enhanced by perfusion single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI) or evaluation of cognitive abilities. Extended examination using MRI and perfusion SPECT showed that the evaluation of the mesencephalon/pons ratio, mesencephalic volume decrease, the Magnetic Resonance Parkinsonism Index (MRPI) and frontal perfusion should be considered more feasible than screening cognitive evaluation in MSA-P and PSP-P with a 3–6-year duration of symptoms. MDPI 2022-02-02 /pmc/articles/PMC8871165/ /pubmed/35204476 http://dx.doi.org/10.3390/diagnostics12020385 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alster, Piotr Nieciecki, Michał Migda, Bartosz Kutyłowski, Michał Madetko, Natalia Duszyńska-Wąs, Karolina Charzyńska, Ingeborga Koziorowski, Dariusz Królicki, Leszek Friedman, Andrzej The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT) |
title | The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT) |
title_full | The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT) |
title_fullStr | The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT) |
title_full_unstemmed | The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT) |
title_short | The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT) |
title_sort | strengths and obstacles in the differential diagnosis of progressive supranuclear palsy—parkinsonism predominant (psp-p) and multiple system atrophy (msa) using magnetic resonance imaging (mri) and perfusion single photon emission computed tomography (spect) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871165/ https://www.ncbi.nlm.nih.gov/pubmed/35204476 http://dx.doi.org/10.3390/diagnostics12020385 |
work_keys_str_mv | AT alsterpiotr thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT niecieckimichał thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT migdabartosz thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT kutyłowskimichał thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT madetkonatalia thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT duszynskawaskarolina thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT charzynskaingeborga thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT koziorowskidariusz thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT krolickileszek thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT friedmanandrzej thestrengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT alsterpiotr strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT niecieckimichał strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT migdabartosz strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT kutyłowskimichał strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT madetkonatalia strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT duszynskawaskarolina strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT charzynskaingeborga strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT koziorowskidariusz strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT krolickileszek strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect AT friedmanandrzej strengthsandobstaclesinthedifferentialdiagnosisofprogressivesupranuclearpalsyparkinsonismpredominantpsppandmultiplesystematrophymsausingmagneticresonanceimagingmriandperfusionsinglephotonemissioncomputedtomographyspect |